Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

147 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Rogaratinib in patients with advanced cancers selected by FGFR mRNA expression: a phase 1 dose-escalation and dose-expansion study.
Schuler M, Cho BC, Sayehli CM, Navarro A, Soo RA, Richly H, Cassier PA, Tai D, Penel N, Nogova L, Park SH, Schostak M, Gajate P, Cathomas R, Rajagopalan P, Grevel J, Bender S, Boix O, Nogai H, Ocker M, Ellinghaus P, Joerger M. Schuler M, et al. Among authors: ocker m. Lancet Oncol. 2019 Oct;20(10):1454-1466. doi: 10.1016/S1470-2045(19)30412-7. Epub 2019 Aug 9. Lancet Oncol. 2019. PMID: 31405822 Clinical Trial.
Phase Ib/II study of the pan-cyclin-dependent kinase inhibitor roniciclib in combination with chemotherapy in patients with extensive-disease small-cell lung cancer.
Cho BC, Dy GK, Govindan R, Kim DW, Pennell NA, Zalcman G, Besse B, Kim JH, Koca G, Rajagopalan P, Langer S, Ocker M, Nogai H, Barlesi F. Cho BC, et al. Among authors: ocker m. Lung Cancer. 2018 Sep;123:14-21. doi: 10.1016/j.lungcan.2018.04.022. Epub 2018 Apr 27. Lung Cancer. 2018. PMID: 30089585 Free article. Clinical Trial.
Phase I dose-escalation studies of roniciclib, a pan-cyclin-dependent kinase inhibitor, in advanced malignancies.
Bahleda R, Grilley-Olson JE, Govindan R, Barlesi F, Greillier L, Perol M, Ray-Coquard I, Strumberg D, Schultheis B, Dy GK, Zalcman G, Weiss GJ, Walter AO, Kornacker M, Rajagopalan P, Henderson D, Nogai H, Ocker M, Soria JC. Bahleda R, et al. Among authors: ocker m. Br J Cancer. 2017 Jun 6;116(12):1505-1512. doi: 10.1038/bjc.2017.92. Epub 2017 May 2. Br J Cancer. 2017. PMID: 28463960 Free PMC article. Clinical Trial.
Phase 1 Dose Escalation Study of the Allosteric AKT Inhibitor BAY 1125976 in Advanced Solid Cancer-Lack of Association between Activating AKT Mutation and AKT Inhibition-Derived Efficacy.
Schneeweiss A, Hess D, Joerger M, Varga A, Moulder S, Tsimberidou AM, Ma C, Hurvitz SA, Rentzsch C, Rudolph M, Thiele S, Boix O, Wilkinson G, Lagkadinou E, Ocker M. Schneeweiss A, et al. Among authors: ocker m. Cancers (Basel). 2019 Dec 10;11(12):1987. doi: 10.3390/cancers11121987. Cancers (Basel). 2019. PMID: 31835495 Free PMC article.
First-in-human phase I study of the bromodomain and extraterminal motif inhibitor BAY 1238097: emerging pharmacokinetic/pharmacodynamic relationship and early termination due to unexpected toxicity.
Postel-Vinay S, Herbschleb K, Massard C, Woodcock V, Soria JC, Walter AO, Ewerton F, Poelman M, Benson N, Ocker M, Wilkinson G, Middleton M. Postel-Vinay S, et al. Among authors: ocker m. Eur J Cancer. 2019 Mar;109:103-110. doi: 10.1016/j.ejca.2018.12.020. Epub 2019 Jan 31. Eur J Cancer. 2019. PMID: 30711772 Clinical Trial.
147 results